Liver Disease and Fibrosis Assessment in Substance Use-Related Disorders.

about

Assessment of Hepatic Impairment and Implications for Pharmacokinetics of Substance Use Treatment.Drug-Drug Interactions and Diagnostics for Drug Users With HIV and HIV/HCV Coinfections: Introduction.

P2860

Q38927192-A23BA2C7-27F9-4D02-BB07-257429FA4888 Q40306582-068FB7AE-7C9B-40AF-8935-1CAD607405CB

P2860

Liver Disease and Fibrosis Assessment in Substance Use-Related Disorders.

Item

http://www.wikidata.org/entity/Q40306589

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年論文

@yue

2017年論文

@zh-hant

2017年論文

@zh-hk

2017年論文

@zh-mo

2017年論文

@zh-tw

2017年论文

@wuu

2017年论文

@zh

2017年论文

@zh-cn

name

Liver Disease and Fibrosis Assessment in Substance Use-Related Disorders.

@en

type

Item

label

Liver Disease and Fibrosis Assessment in Substance Use-Related Disorders.

@en

prefLabel

Liver Disease and Fibrosis Assessment in Substance Use-Related Disorders.

@en

P1476

Liver Disease and Fibrosis Assessment in Substance Use-Related Disorders.

@en

P2093

Anthony Martinez

http://www.w3.org/2001/XMLSchema#string

Marija Zeremski

http://www.w3.org/2001/XMLSchema#string

P2860

Alcoholic hepatitis and HCV interactions in the modulation of liver disease

Meta-analyses of FibroTest diagnostic value in chronic liver disease.

Pharmacokinetics of opioids in liver disease.

Hepascore: an accurate validated predictor of liver fibrosis in chronic hepatitis C infection.

Transient elastography: a new noninvasive method for assessment of hepatic fibrosis.

Assessment of methadone clinic staff attitudes toward hepatitis C evaluation and treatment.

Hepatitis C virus-related knowledge and willingness to receive treatment among patients on methadone maintenance

Hepatitis C virus control among persons who inject drugs requires overcoming barriers to care.

FibroScan (vibration-controlled transient elastography): where does it stand in the United States practice.

Restrictions for Medicaid Reimbursement of Sofosbuvir for the Treatment of Hepatitis C Virus Infection in the United States.

P304

164-168

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1002/CPDD.312

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2017-03-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28263455

http://www.w3.org/2001/XMLSchema#string

Liver Disease and Fibrosis Assessment in Substance Use-Related Disorders.

about

P2860

P2860

Liver Disease and Fibrosis Assessment in Substance Use-Related Disorders.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P577

P698

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P577

P698